急性淋巴细胞白血病免疫与靶向治疗的临床应用  

Clinical application of immune and targeted therapy for acute lymphoblastic leukemia

作　　者：洪梅[1] 李紫璇 HONG Mei;LI Zixuan(Institute of Hematology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院血液病研究所,武汉430022

出　　处：《临床血液学杂志》2024年第5期312-317,325,共7页Journal of Clinical Hematology

摘　　要：近年来,免疫与靶向治疗由于其独特的作用机制及较弱的不良反应成为急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)治疗中备受关注的新型疗法,许多研究致力于推出针对不同疾病阶段,特别是复发/难治ALL患者的新型免疫与靶向药物联合或不联合化疗的治疗方案,取得了显著的临床疗效,对ALL患者临床用药具有较大的指导价值。现针对ALL热点免疫与靶向治疗方案进行综述。In recent years,immunotherapy and targeted therapy have attracted great concern in the field of acute lymphoblastic leukemia(ALL)due to its unique mechanism and weak toxicity.Many studies are committed to introducing novel immune and targeted drugs combined with or without chemotherapy for different disease stages,especially for relapsed/refractory ALL patients,and have achieved significant clinical efficacy.These studies have great value for guiding the clinical medication of ALL patients.This article reviews the hotspot immunotherapy and targeted therapy for ALL.

关 键 词：急性淋巴细胞白血病 免疫治疗 靶向治疗 

分 类 号：R733.71[医药卫生—肿瘤]